The Promise of Oncoimmunology: Integrating Immunotherapy with Conventional Cancer Treatments

  title={The Promise of Oncoimmunology: Integrating Immunotherapy with Conventional Cancer Treatments},
  author={P. CheenaChawla and A. Chawla},
  journal={Journal of Integrative Oncology},
The goal of immunotherapy is to eliminate cancer cells through the transfer of ex vivo expanded and activated immune cells. Immune cells such as Dendritic Cells (DCs), Natural Killer (NK) cells, Cytotoxic T-cells, and Cytokine Induced Killer (CIK) cells have been investigated for active immunotherapy against cancer. Besides, the passive transfer of Monoclonal Antibodies has been an effective treatment for some cancers. However, for immunotherapy to become the mainstay of treating various… Expand
Review on Cancer Therapy
This review discusses the employment of liposomes and micelles in cancer medical aid and makes an attempt to produce some current info concerning the clinical standing of many of those Nano carrier-based medicines. Expand
Types of Cancer and Surgery in Rats (Rattus norvegicus)
The tumor suppressor gene (p53) will helps to supress the cancer genes in humans along with in animals, called as “Peto's paradox”. Expand
Research and Reviews: Journal of Pharmaceutical Analysis 'Elvitegravir' and its Validation: A Review
Most antivirals are considered relatively harmless to the host, and therefore can be used to treat infections, and should be distinguished from viricides, which are not medication but deactivate or destroy virus particles, either inside or outside the body. Expand
Elvitegravir and its Validation: A Review
Most antivirals are considered relatively harmless to the host, and therefore can be used to treat infections, and should be distinguished from viricides, which are not medication but deactivate or destroy virus particles, either inside or outside the body. Expand
Cycloastragenol(Telomeres Activator) and its relation with Cancer: A Brief Review
The main theme involved in this article is to show the effect of cycloastragenol compound in curing the cancer disease. Cycloastragenol is extracted from astragalus root which is available in fewerExpand
Role of Immunoglobulin against Infections
ABSTRACT Immunoglobulin is nothing but an antibody that is produced by the white blood cells present in our body. It is very useful in the critical situation of immune response. Antibodies areExpand


Cell technologies in immunotherapy of cancer.
Optimization of the preparation of autologous and allogeneic antitumor vaccines and development of tumor cell culture bank for the experiments onAllogeneic vaccination are held and clinical evaluation of autOLOGous vaccine therapy by bone marrow precursors of dendritic cells is conducted. Expand
Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges
This review focuses on the critical issues related to the clinical outcomes of CAR-based adoptive immunotherapy and discusses the rationales to refine this new cancer therapeutic modality. Expand
Dendritic cells: tools and targets for antitumor vaccination
Novel insights in antigen loading, activation and migration of dentritic cells and their impact on the application of ex vivo-generated dentritic cell vaccines are reviewed and possible obstacles that should be overcome to induce long-lasting immunity in therapeutic settings will be discussed. Expand
Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors
The biologic characteristics of CIK cells are described, focusing on those aspects that may favor their clinical translation, and the easy availability of large amounts of expandedCIK cells and their MHC-unrestricted tumor killing, potentially effective against many tumor types. Expand
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.
The results of a proof-of-concept clinical trial in which patients with relapsed or refractory indolent B-cell lymphoma or mantle cell lymphoma were treated with autologous T cells genetically modified by electroporation with a vector plasmid encoding a CD20-specific chimeric T- cell receptor and neomycin resistance gene show the safety, feasibility, and potential antitumor activity of adoptive T-cell therapy using this approach. Expand
Vaccination of patients with solid tumours.
The findings generated by trials based on the administration of peptides or DNA-encoding antigens are discussed to highlight the limits of this therapeutic approach; however, this approach has resulted in some complete and durable regressions, although still in a unsatisfactory small number of cases. Expand
Inflammation and immune surveillance in cancer.
The processes of cancer immunoediting and inflammation-induced cancer are introduced and what is currently known about the role of danger signal receptors in cancer development and progression is discussed. Expand
Recent advances in therapeutic cancer vaccines.
  • J. Schlom
  • Medicine
  • Cancer biotherapy & radiopharmaceuticals
  • 2012
Sipuleucel-T consists of autologous peripheral blood mononuclear cells, including antigen-presenting cells that have been activated ex vivo with a recombinant fusion protein. Expand
Third generation dendritic cell vaccines for tumor immunotherapy.
Based on phenotype, chemokine-directed migration, facility to process and present antigens, and stimulatory capacity to polarize Th1 responses in CD4+ T cells, induce antigen-specific CD8+ CTL and activate natural killer cells, these young DCs display all the important properties needed for initiating good antitumor responses in a vaccine setting. Expand
Dendritic cells transduced with a PSMA-encoding adenovirus and cocultured with autologous cytokine-induced lymphocytes induce a specific and strong immune response against prostate cancer cells.
The data demonstrate that dendritic cells from healthy donors transduced with a PSMA-expressing adenovirus and cocultured with autologous CIKs, induce a PSma-specific, strong immune response against PCa cells, which may have a potential for an adoptive immunotherapy for patients with advanced PCa. Expand